Regulatory Immunotherapy in Bone Marrow Transplantation by Morales-Tirado, Vanessa et al.
Review Article
TheScientiﬁcWorldJOURNAL (2011) 11, 2620–2634
ISSN 1537-744X; doi:10.1100/2011/768948
 
Regulatory Immunotherapy in Bone Marrow
Transplantation
Vanessa Morales-Tirado, Wioleta Luszczek, Marié van der Merwe, and Asha Pillai
Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital,
262 Danny Thomas Place, Memphis, TN 38105, USA
Received 10 August 2011; Accepted 12 October 2011
Academic Editors: N. Miyahara, Y. Renaudineau, and J. Sidney
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1. INTRODUCTION
Elegant studies by Barnes et al. [1, 2] demonstrated that the infusion of allogeneic bone marrow cells
may destroy recipient tumor cells, indicating the possibility of cytotherapeutic antitumor potential in the
transplanted allogeneic cellular graft (graft-versus-tumor activity, GVT). Some animals clearing leukemic
cells died of a secondary “wasting disease” consisting of diarrhea, weight loss, skin inﬂammation, and
liver disease. This was the ﬁrst clinical description of lethal graft-versus-host disease (GVHD) in a murine
model[3].ParallelstudiesofhumanbonemarrowtransplantationformalignanciesbyMatheandcolleagues
focused on attempts to achieve GVT without fatal GVHD, but these were complicated by lack of sustainable
engraftment of donor hematopoietic cells. By combining total body irradiation (TBI) with infusion of
allogeneic bone marrow, Thomas’s group in 1959 demonstrated the ﬁr s tl e u k e m i ac u r eb yH S C T[ 4].
Although this patient died from complications of GVHD, no residual leukemia cells were found. It became
evident that although allotransplantation could be curative for hematologic malignancies, GVHD would
remain the major hurdle for success. Finally, in 1965, Mathe’s group reported a case of successful long-
term engraftment without GVHD after allogeneic bone marrow transplantation [5].
Nearly 50 years later, GVHD and graft rejection continue to limit the curative application of
allogeneic bone marrow transplantation (BMT), both for malignant and nonmalignant hematologic
conditions. GVHD is mediated by an immune attack by the donor effector T cell population within the graft
against key target tissues of the recipient or graft-versus-host (GVH) reactivity, whereas graft rejection is
mediated dominantly by effector T and NK cells responses of the recipient against the donor graft, termed
host-versus-graft (HVG) reactivity [6, 7]. Both GVH and HVG reactivities are augmented immunologically
by tissue damage and release of proinﬂammatory cytokines, which characterize conventional TBI-
containing pretransplant conditioning regimens. In 1966, Billingham identiﬁed the criteria associated with
the development of GVHD as (1) MHC disparity between donor and recipient, (2) immunocompetent cells
in the graft, and (3) the ability of the host to accept the graft (relative HVG hyporeactivity) [8]. The target
organsofGVHDincludetheskin,liver,andtheintestinaltract.Studiesusingantithymocyteglobulin(ATG),
and more recently the use of monoclonal antibodies to deplete T lymphocytes, revealed that contaminating
mature T cells from the donor recognize the recipient’s histocompatibility antigens. Paradoxically, T cells
are also required for cytotoxic T lymphocyte (CTL) effector function, which are central to GVT activity.
Thus, the “Holy Grail” in allotransplantation is to maintain GVT (and antimicrobial/antiviral) activity while
facilitating the engraftment of the donor hematopoietic stem cells, and avoiding GVHD mediated by mature
T cells within the donor graft.
The immune mechanisms regulating GVHD need to be clearly understood for development of
rational treatment, and ideally, better preventive strategies. Understanding immunoregulatory networks in
both murine models and man is thus indispensable for novel therapeutics. This review will focus on our
current understanding of the immunobiology of regulatory cells from both the innate and adaptive arms of
the immune system as vehicles for treatment and prevention of GVHD (Figure 1), using both preclinical
and clinical studies in allogeneic BMT.
2. INNATE REGULATORY CELLS: NATURAL KILLER T CELLS
An effective immune response requires the integration of the innate and adaptive arms of immunity,
initiated by triggering of antigen-presenting cells (APCs). In allotransplantation, APCs of both recipient
and donor are dominant sensors of the disparity between major histocompatibility complex (MHC) and
peptide complexes, and they play roles in both antigen presentation and costimulation. Immunoregulatory
cells of the innate immune system can modulate the function of and be modulated by both donor and
recipient APCs.
Natural Killer T (NKT) cells (reviewed in [6, 9, 10]) are considered innate immune regulatory
cells due to the acquisition of effector function during development, rather than postantigen exposure.
During an early immune response, recruited NKT cells produce high concentrations of cytokines that
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FIGURE 1: Model for host-donor immunoregulation after nonmyeloablative BMT. Figure illustrating key
regulatory populations in host and donor and the potential for interactive regulation across major and
minor histocompatibility complex barriers after allogeneic BMT. NKT cells, through potent of cytokines
secretion including IL-4, can directly regulate the effector T cells responsible for GVHD; NKT cells can
also induce the activation and proliferation of Treg from the donor graft, which in turn regulate effector T-
cell-mediated GVHD. NKT: natural killer T; Th2: T-helper type 2; Tr1: Foxp3negCD4+IL-10+ regulatory T cell;
IL-4: interleukin-4.
alter the microenvironment for activation and recruitment of other immune cells including T effector cells
(CD3+CD4+CD25neg and CD3+CD8+CD25neg), CD4+CD25+Foxp3+ regulatory cells (Treg), and both
professional APCs such as dendritic cells (DCs) and nonprofessional APCs. NKT cells can be divided
into two main subsets. Both subsets are activated through glycolipid antigen presentation by the MHC
Class I-like molecule CD1d. The endogenous glycolipid ligand(s) presented by CD1d remains elusive,
though a subject of aggressive investigation. The exogenous glycolipid α-galactosylceramide (α-GalCer)
[11], derived from the marine sponge, is the prototypical reagent used for NKT cell activation. Contrary to
conventional effector T cells, the response of NKT cells to cognate antigens is not restricted by MHC-Class
I or II molecules. Type I NKT cells, commonly known as invariant NKT (iNKT), have an invariant TCR-Jα
chain. Type II NKT cells are less well understood, can have a noninvariant TCR-Jα chain, and may have
diverse TCR-Vα and -Vβ rearrangements.
3. IMMUNOREGULATION BY NKT CELLS
Pivotal studies from multiple laboratories have characterized a novel subpopulation of CD4−CD8− (DN)
NKT cells which not only do not initiate GVHD, but also inhibit the graft-versus-host immune response
following MHC-mismatched BMT. Using C57BL/6 (H-2b) → BALB/c (H-2d)a n dB A L B / c→ C57BL/6
allogeneic transplant models, Zeng and colleagues compared peripheral blood (PB)- and bone marrow
(BM)-derived sorted CD4+ and CD8+ T cells of donor mice to T cell depleted bone marrow injected
into lethally irradiated host mice in their ability to induce GVHD [12]. PB-derived control cells were
potent inducers of GVHD. Using NK1.1 selection, known now to select both noninvariant and a subset of
iNKT cells, BM-derived sorted cells were tested for their ability to induce GVHD. NK1.1− effector CD4+
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TABLE 1: Murine models of immunoregulatory cells in hematopoietic cell transplantation.
Immunoregulatory cell Reference Model Contributions
Natural killer T (NKT)
Cells
Lan et al. [17]
MHC-mismatched
C57BL/6→BALB/c
(i) TLI and ATS regimen
increases recipient
NK1.1+TCRαβ+ cells.
(ii) Recipient NKT cells
mediate GVHD protection.
Hashimoto et al. [18]
MHC-mismatched
BALB/c→C57BL/6
(i) α-Gal-Cer treatment of
recipients.
(ii) Recipient NKT cells
mediate GVHD protection
via IL-4.
Pillai et al. [19]
MHC-mismatched
C57BL/6→BALB/c
(i) TLI/ATS regimen.
(ii) Recipient NKT cells
regulate GVHD without
inhibiting GVT.
Leveson-Gower et al.
[20]
MHC-mismatched
C57BL/6→BALB/c
(i) Donor NKT cells regulate
GVHD without inhibiting
GVT, via IL-4.
Regulatory T cells
(Treg)
Taylor et al. [54] Ex vivo allo-MLR:
(i) Tolerance is dependent on
presence of CD4+CD25+ T
cell fraction.
Hoffmann et al. [55]
MHC-mismatched
C57BL/6→BALB/c
(i) Donor Treg protects
against lethal GVHD induced
by donor cells through IL-10
production.
Edinger et at. [56]
MHC-mismatched
C57BL/6→BALB/c
(i) Donor Treg GVHD
protection does not alter
GVT.
NKT-Treg interaction Pillai et al. [21]
MHC-mismatched
C57BL/6→BALB/c
(i) TLI/ATS regimen.
(ii) Recipient iNKT induces
donor Treg proliferation to
suppress GVHD.
MHC: mouse major histocompatibility complex; TLI: total lymphoid irradiation; ATS: rabbit antimouse thymocyte serum; α-Galcer: α-
galactosylceramide (NKT-speciﬁc glycolipid ligand); IL-4: interleukin 4; IL-10: interleukin 10.
and CD8+ cells, which are high IFN-γ producers, induced potent GVHD. This GVHD was ameliorated
by the infusion of NK1.1+ T cells (which produced both IFN-γ and IL-4), suggesting that NK1.1+ cells
were able to regulate GVHD induced by the NK1.1− effector T cells. To test the possible contribution of
cytokine secretion from the NK1.1+ T cell subset in regulation of GVHD, the experiment was repeated
using NK1.1+ cells from IL-4-deﬁcient donor mice. In sum, the outcome of these experiments showed for
the ﬁrst time that GVHD is induced by effector NK1.1− T cells and regulated NK1.1+ NKT cells, and
that amelioration of GVHD by NK1.1+ NKT cells is IL-4-dependent, at least in the setting of a major
alloresponse such as MHC-mismatched BMT (Table 1). Though this data was focused on the regulatory
capacity of donor NKT cells on donor effector T cell-mediated GVHD, later studies have demonstrated
roles for NKT cells in alloregulation across donor-recipient MHC barriers in nonmyeloablative BMT (see
below).
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3.1. Murine NKT Cells
Murine NKT cells constitute 0.2–0.5% of total lymphocytes. They are most frequent in liver tissue and least
abundant in lymph nodes [9]. Like conventional T cells, NKT cells undergo maturation from prethymic
CD3+ bone marrow precursors under the inﬂuence of thymic antigen exposure. Thymic cortical positive
selection of NKT cells is strictly dependent on CD1d expressed on thymic epithelial cells (TEC). This has
been demonstrated by absence of both iNKT and noninvariant NKT cells in CD1d knock-out (KO) mice
and in CD1d KO mice given myeloablative bone marrow transplants from wild-type syngeneic donors, in
which hematopoietically derived populations but not somatic epithelial tissues express CD1d. Murine NKT
cells express the invariant Vα14 TCR-α chain and the Jα18-joining segment. Jα18 KO mice are deﬁcient
in iNKT cells, demonstrating the conserved nature of the Vα14Jα18 TCR [13] rearrangement in invariant
NKT cells.
Phenotypically, murine NKT cells can be divided into subpopulations based on the presence or
absence of the CD4 coreceptor molecule. NKT cells can have a CD4+ single positive (SP) or a CD4−CD8−
double negative (DN) phenotype. More than 70% of the total iNKT fraction in mice is subsumed by the SP
subset. The functional characterization of SP versus DN iNKT has been complicated by differences in the
model systems used and organ sites from which iNKT cells were isolated, which could alter the reported
phenotype. These represent areas ripe for further study, in particular with respect to immunomodulatory
roles of these cells. The function of a CD8+ subpopulation of iNKT cells in mice remains unclear. CD4+
NKT cells produce both Th1- and Th2-type cytokines (IFN-γ and IL-4, resp.), whereas CD8+ NKT cells
show a Th1-type cytokine bias. Other cytokines produced by NKT cells include TNF-α, IL-2, IL-10, IL-
13, IL-17, IL-21, IL-22, and GM-CSF. The relative functions of the noninvariant NKT versus iNKT cells
in murine systems is similarly in need of speciﬁc comparative study for a number of immunoregulatory
functions ascribed to NKT cells as a whole. The combination of the surface markers TCRαβ,C D 4 ,
CD8, and NK cell activation markers such as NK1.1 (DX5 in the BALB/c strain) and reactivity with α-
GalCer-loaded CD1d tetramer reagents aid in the identiﬁcation and isolation of NKT cells from tissues.
Development of a sensitive and speciﬁc anti-Vα14 monoclonal antibody would greatly aid the ﬁeld of
murine iNKT study.
3.2. Human NKT Cells
FrequencyofhumanNKTcellsinthebloodishighlyvariableandmuchlowerthanthatofmurineNKTcells
(0.01–0.5%). Human NKT cells share some key phenotypic similarities with their murine counterparts. Like
murine NKT cells, human NKT cells acquire effector function during development and not after maturation.
They can similarly be divided into two main groups: invariant and noninvariant (Types I and II). In humans,
type I (iNKT) expresses the invariant Vα24 TCR-α chain subset [14], the Jα18 conserved joining segment,
and the Vβ11 chain. Cellular activation remains glycolipid dependent in the context of the MHC Class I-like
molecule CD1d, although conﬂicting data exists suggesting other mechanisms of activation for other types
of antigens, including viral antigens. Whereas mice express only the CD1d isoform, humans demonstrate
4 isoforms of CD1 (CD1a–d). To date, only CD1d has been shown to present glycolipid antigen to human
NKT cells.
Human iNKT cells include three subsets: CD4+,C D 8 +,a n dC D 4 −CD8− (DN) cells, with the
dominant fraction in most studies being DN iNKT cells. High-purity isolation can be achieved by 6B11
monoclonal antibody (directed against the Vα24 chain-Jα18 segment of the CDR3 loop of TCR) [15, 16]
in conjunction with anti-CD3. Less than 40% of the cells are single positive, even during ex vivo expansion
of CD3+Vα24+ cells (Figure 2(a)). Cytokine production has been characterized mainly using PB-derived
NKT cells. In addition to IFN-γ and IL-4, human PB NKT cells are known to secrete TNF-α, IL-10, IL-13,
and GM-CSF. Contrary to murine NKT cells, human NKT cells, both DN and CD8+, exhibit a predominant
Th1-type cytokine proﬁle [6]. Interestingly, differences in NKT cell cytokine proﬁle (polarization) may
also be determined by age or stage of maturation. Stimulated human cord blood-derived NKT cells
have been shown to maintain a predominantly Th2 phenotype in comparison to adult PB NKT cells,
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FIGURE 2: Phenotype of expanded iNKT cells. (a) PBMCs cultured for 7 days with α-GalCer in combination
with rhIL-2 and rhIL-7 followed by FACS-based cell sorting for CD3+Vα24+ cells. Sorted iNKT cells were
cultured with allo-PBMCs feeders, anti-CD3 mAb, and rhIL-2 and rhIL-7 for 21 days. (b) Cytokine proﬁle of
expanded (day 28) iNKT cells. Cellular cultures of FACS-sorted/expanded CD3+CD4negVα24+ cells were
stimulated for 5 hours with media alone or media + α-GalCer. Samples were analyzed using BD LSRII
equipment and FlowJo 9.3.2 software. GrB: intracellular Granzyme B.
though this can be shifted by growing NKT cells in Th1-polarizing conditions. As shown in Figure 2(b),
expanded PB-derived CD4+ NKT cells exhibit a Th2 phenotype (predominant IL-4-producing cells and
low/null IFN-γ production), even when the prototype αGal-Cer was used for a 5-hour restimulation at
day 28 after cellular expansion (Luszczek, Morales-Tirado and Pillai, Unpublished). Our preliminary data
suggests that expanded human iNKT cells maintain a Th2 cytokine proﬁle during cellular expansion,
making these cells an attractive tool for immunotherapy of Th1 inﬂammatory disorders including GVHD.
4. GRAFT-VERSUS-HOST DISEASE REGULATION BY NKT CELLS
The CD4−CD8− DN iNKT subpopulation is associated with direct antitumor activity and modulation of
antitumor activity of other key immune populations such as NK cells, and transplant associated effector
functions such as GVT. Type II NKT cells suppress antitumor surveillance in certain model systems,
although these models were limited by the nature of the tumor model and the methods of investigation of
antitumor response. In addition, NKT cells contribute to the maintenance of immune tolerance to allografts
in both solid organ (cardiac) transplantation and in HSCT.
The need to reduce the undesirable toxicity of conventional myeloablative pretransplant con-
ditioning led to the development of less intense pre-transplant preparative regimen or “conditioning”
(reduced intensity conditioning, RIC) therapy that retains desirable immune effects such as GVT with
reduced organ toxicity and transplant-related mortality. Nonmyeloablative conditioning relies more on
immunosuppression and immune modulation and less on chemotherapy and/or radiation-mediated host
immune ablation. Total lymphoid irradiation (TLI) is a nonmyeloablative regimen shown to have potent
immunosuppressive effects in patients with Hodgkin’s lymphoma, and other diseases. When applied as
part of pretransplant conditioning of recipients for BMT, TLI protects recipients against GVHD in part
by augmenting immunoregulatory cell function in both recipient and donor when compared to TBI. In
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TLI conditioning, recipient/host NKT cells persist due to their resistance to radiation-induced apoptosis
(compared to conventional T lymphocytes) as well as bone marrow-sparing effects of a nonmyeloablative
regimen. Murine studies have demonstrated that TLI in combination with rabbit antimouse thymocyte
serum (ATS) preferentially depletes peripheral effector T cells, causing an increase in the relative
fraction of NK1.1+TCRαβ+ cells in spleen and liver of recipient mice to more than 90% of all T
cells in recipient mice [17]. This increase is associated with a Th2-cytokine shift, dominated by IL-
4 production, which appears to be critical to the immunoregulatory capacity of the TLI/ATS regimen
when applied to allo-BMT. Protection from GVHD is lost when NKT cell-deﬁcient recipients are
used, demonstrating a central role for host NKT cells in this process [6]. Shortly thereafter, studies
demonstrated in a different murine transplant model [18] that the stimulation of recipient NKT cells
with the exogenously derived NKT-speciﬁc glycolipid ligand α-galactosylceramide can allow GVHD
protection, and that this protection is mediated by recipient NKT cell IL-4 acting on T cells within the
donor graft.
Additional studies performed by Pillai et al. showed that iNKT cells do not inhibit the GVT
potential of allogeneic BMT. Splenocytes from wild type, CD8−/−, perforin−/−, or Fas ligand−/− donors
were used and demonstrated that CD8+ peripheral T cells from the donor graft mediated GVT via a
perforin-dependent pathway [19]. Later studies have conﬁrmed using direct bioluminescence imaging (BLI)
techniques that murine NKT cells of donor type can regulate GVHD without inhibiting GVT [20]. Given
the ability of NKT cells to readily secrete cytokines that potently alter the immune microenvironment,
we have continued to pursue the role of NKT cells in GVHD protection. Using the same murine model
system, we have reported that recipient-type iNKT cells enriched after TLI/ATS conditioning are capable of
inducing and/or maintaining the regulatory function of donor-type Foxp3+ Treg from among the peripheral
T cells within the graft in vivo, and that this critical host-donor immunoregulatory interplay is required
for the potent GVHD protection seen after TLI/ATS + BMT [21]. The induction and maintenance of
donor Treg function by recipient iNKT cells was demonstrated to depend upon IL-4 secretion, which
can be established after TLI/ATS by recipient Th2-polarized iNKT cells. Our most recent results (van der
Merwe and Pillai, Unpublished) demonstrate that the TLI/ATS-induced Th2 polarized milieu allows the
persistence of a recipient BM-derived APC population with characteristics of myeloid-derived suppressor
cells (MDSCs) which suppresses CD8+ T cells, and may enhance the Foxp3+ Treg fraction of the donor
graft.
The ﬁndings in these murine preclinical models have largely been translated to human clinical
trials for acute myelogenous leukemia (AML), non-Hodgkin’s lymphoma (NHL), and chronic lymphocytic
leukemia (CLL). Lowsky and colleagues [22] applied TLI/ATG (antithymocyte globulin) conditioning
prior to matched sibling donor (MSD) and matched unrelated donor (MUD) HSCT for heavily pretreated
adults with AML and mantle cell lymphomas. Thirty-seven initial patients received TLI/ATG, followed
by infusion of G-CSF-mobilized PB stem cell grafts. Signiﬁcant reduction in the incidence and severity
of acute GVHD was observed. As in the murine preclinical studies, a profound decrease in the absolute
number of conventional T cells was observed. NKT cells were increased by a factor of 10 among all the
CD3+ T cells. Antitumor activity was preserved, as evidenced by relapse rate. A recent review of the entire
cohort has conﬁrmed this low incidence of GVHD, low mortality, and preserved GVT [23].
5. ADAPTIVE IMMUNOREGULATORS: Foxp3+ NATURAL REGULATORY
T CELLS (Treg)
Evidence exists that signiﬁcant crosstalk can occur between the innate regulators described earlier and
adaptive regulatory T cells (Treg) during a coordinated immune response, outside of the context of the
MHC immune barriers of BMT. Treg are involved both in the pathology of and protection against different
immune-mediateddiseases.Tregareclassiﬁedbasedontheirorigin(thymicallyderivedversusperipherally-
derived), signature transcription factor (Foxp3), phenotypic surface markers (CD45 RA versus RO,
HLA-DR), and cytokine proﬁle (TGF-β or IL-10) [24]. Treg possessing an α-TCR can express the
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coreceptors CD4 or CD8, whereas γδ-TCR-expressing Treg may be double negative. In this section, we
concentrate on CD4+TCRα+ Treg that originate naturally in the thymus (nTreg).
Sakaguchi’s [25] and Powrie’s [26] groups independently described the presence of suppressive
CD3+CD4+CD25+ T cells in the thymus in mice and humans, respectively. Papiernik et al. and
Romagnani’s [27] group demonstrated, using intrathymic labeling, the migration pattern of these cells
from thymus to the periphery [28]. Positive selection in the thymus is mediated by MHC Class II-positive
thymic cortical epithelial cells (TECs) and requires that Treg have high TCR afﬁnity for MHC-peptide
complexes. Contrary to their anergic phenotype in vitro, peripheral Treg proliferate upon receiving cytokine
and costimulation-derived signals, such as IL-2 signaling and CD28 costimulation.
Resistance to apoptosis might be conferred by the presence of the surface molecule glucocorticoid-
induced TNFR-related protein (GITR). There is great speculation about the mechanisms by which
Treg suppress [29–32]. In general, immunosuppression requires TCR-dependent stimulation, cell-to-cell
contact (CTLA-4/B7, cytolytic molecules), presence of soluble factors (cytokines, adenosine), and cellular
competition with effector T cells for locally available cytokines (γ-chain cytokines including IL-2).
Dysregulation of immune responses such as an overexpression of proinﬂammatory cytokines and
reduction of anti-inﬂammatory cytokines in autoimmunity, and immunosuppression of cytolytic responses
in tumors, has signiﬁcant implications for the application of regulatory T cells in immunotherapy for
malignant and nonmalignant disorders.
5.1. Murine Regulatory T Cells
In 2000, Sakaguchi and colleagues demonstrated that murine cells with a regulatory capacity express high
and sustained levels of the IL-2 receptor-α chain, CD25. CD3+CD4+CD25+ T cells became the most
physiologically relevant Treg population, found to comprise almost 10% of the total CD3+CD4+ T cell
population in the periphery. The transcription factor Forkhead box P3 (FOXP3) is expressed exclusively
in all murine Treg [33–35], making it the best candidate for Treg identiﬁcation and identifying Treg
as a distinct cell lineage. Unfortunately, Foxp3 staining requires ﬁxation and permeabilization of the
cells, making them non-viable for further experimentation. Therefore, a signiﬁcant number of surface
markers have been screened in an attempt to identify a unique surface phenotype allowing the isolation
of viable Treg. To date, the best surface marker proﬁle for murine Treg with alloregulatory capacity is
CD3+CD4+CD25+GITR+ [36, 37]. There is evidence that GITR is overexpressed in tolerant mouse skin
grafts when compared to rejected grafts [38]. It is important to emphasize that GITR or other surface
markers do not themselves confer regulatory capacity. However, ectopic expression of Foxp3 transforms
conventional T cells into Treg [34]. A well-described murine GFP reporter system developed by the
Rudensky lab in which GFP-FoxP3 fusion was inserted at the FoxP3 locus (Foxp3-IRES-GFP knock-
in) was generated for FACS-based Treg identiﬁcation and further isolation for ex vivo experimentation
[39]. A second knock-in system developed by Flavell’s group uses a FoxP3-IRES-mRFP bicistronic system
[40]. These systems allowed critical studies that provide essential information about the development and
function of Treg.
5.2. Human Regulatory T Cells
Human Treg exhibit heterogeneity in their phenotype and function compared to their murine coun-
terparts. In the past decade, human Treg have been classiﬁed into more homogenous groups based
on their cell-surface markers. Classically, human Treg display the CD3+CD4+CD25brightCD127lo/−
phenotype [41]. The combination of markers typically used to deﬁne na¨ ıve and memory conventional
T cells serve to further subdivide human Treg (CD3+CD4+CD25brightCD127lo/−CD45RA+ and
CD3+CD4+CD25brightCD127lo/−CD45RO+, resp.). Miyara et al. and Valmori et al. demonstrated that
these subsets differ in their suppressive capacity, with memory Treg being functionally better suppressors
and na¨ ıve Treg exhibiting weaker suppressive capacity [42, 43]. Treg with a “na¨ ıve” phenotype can
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differentiate to acquire a “memory” phenotype. In adult peripheral blood, the memory Treg are more
prevalent than na¨ ıve Treg. In contrast, umbilical cord blood-derived Treg predominantly ﬁt the na¨ ıve
phenotype. Expression of certain costimulatory molecules, such as inducible T-cell costimulator (ICOS),
has also shown a high correlation with suppressive activity of human Treg [44].
A major difference between the murine and human Treg is the speciﬁcity and stability of Foxp3 [45].
In contrast to the exclusive expression of Foxp3 in murine Treg, human Treg may only transiently express
FOXP3. Long-term in vitro studies by Hoffmann et al. [46] showed loss of FOXP3 protein expression
during long-term culture and expansion. Suppressive capacity can be also diminished and accompanied by
the production of proinﬂammatory cytokines such as IL-2, IFN-γ,and IL-17. Besides FOXP3 expression
and stability, a second difference is the presence of 4 distinct FOXP3 isoforms at the mRNA level and 3 at
the protein level [47]. From the 3 different splice variants at the protein level, the full length (FOXP3FL) and
the FOXP3 2 are most common [48, 49]. Du and colleagues showed that RORα (a key regulator of IL-17
expression in conjunction with RORγt) suppresses FOXP3 transcription at exon 2 [50]. The mechanisms by
which human Treg suppress effector responses appear similar to those described for murine Treg, including
cell contact and release of soluble factors such as cytokines and cytolytic molecules [51].
6. IMMUNOREGULATION BY Treg
Onizuka et al., investigated the effect of in vivo administration of an anti-CD25 monoclonal antibody on the
eradication of different leukemia, myeloma, and sarcoma tumors [52]. Additional studies by Sakaguchi’s
group conﬁrmed that tumors regress in speciﬁc mouse strains as a result of depletion of the CD4+CD25+
population [53], suggesting a role for Treg in blocking anti-tumor immunity. Attenuation of the suppressive
function of Treg has been linked to a more robust antitumor activity due to enhancement of T effector
function. Blockade of certain Treg-associated proteins, such as IL-2 cytokine and the surface molecule
CTLA-4, augments antitumor activity.
Treg are essential for tolerance induction. In 2001, Blazar’s group demonstrated that antibody-
mediated depletion of CD25+ T cells abrogated ex vivo induction of tolerance against alloantigens in an
allomixed leukocyte reaction (MLR) using C57BL/6 CD4+ bulk population or C57BL/6 CD4+CD25−
fractionasrespondercellsandB6.C-H2bm12/KhEg(C56BL/6backgroundwithMHC-ClassII-IA mutation)
splenocytes as allostimulators [54]. Tolerance was dependent on the presence of the CD25+ fraction,
because depletion of this population induced hyporesponsiveness to antigen. In vivo, add-back of the
CD4+CD25+ fraction restored allotolerance in comparison with the addition of CD4+CD25− cells,
suggesting a critical role for Treg in regulation of alloresponses. In a series of in vivo experiments using an
allogeneic BMT murine model across MHC-Class I and II barriers, Hoffmann and colleagues [55]h a v e
shown that Treg of donor origin deliver protection against lethal GVHD induced by donor effector T
cells through IL-10 production (Figure 3). Importantly, GVHD protection does not affect GVT exerted
by effector T cells [56]. Subsequent studies by Ermann et al. demonstrated that GVHD prevention in
the MHC-mismatched C57BL/6 → BALB/c setting is afforded by the CD62L+ (L-selectin chemokine
expressing, “na¨ ıve”) fraction [57]. Additional studies [58] demonstrated that regulatory suppression of
GVHD by murine and human Treg preserved thymic and lymphoid architecture of the host and can thereby
accelerate post-HSCT T-cell immune reconstitution.
7. NEW STRATEGIES FOR EX VIVO EXPANSION OF REGULATORY
CELLS FOR IMMUNOTHERAPY
As this review emphasizes, Treg and NKT cells show promise for clinical application in the prevention of
GVHD while simultaneously maintaining GVT. Recently, Martelli’s [59] group has applied immunotherapy
with Treg prior to haploidentical HSCT in patients with hematological malignancies. Following recipient
myeloablative conditioning, donor-derived CD25+ T cells were infused prior to the infusion of the donor
hematopoietic graft. Results were very promising, as only 2 out of 28 patients exhibited GVHD, and patients
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FIGURE 3: Donor CD4+CD25+ T cells, which expand in vivo after a nonmyeloablative HSCT conditioning
regimen, secrete IL-10 but no IL-4 or IL-5. (a) Representative analysis of in vivo expanded donor
H-2Kb+CD4+CD25+ T cells sorted from recipient mouse spleen at day 6 after allogeneic bone
marrow transplantation. (b) Cytokine proﬁle of sorted CD4+CD25+ T cells. H-2Kb+CD4+CD25+ and H-
2Kb+CD4+CD25− splenocytes were sorted from spleens of wild-type C57BL/6 mice (untreated, UNT) or
from wild-type BALB/c hosts conditioned with TLI/ATS, transplanted with bone marrow and spleen cells
from a wild-type C57BL/6 donor, and harvested on day 6 after transplant. A total of 4 × 104 cells/well were
incubated in triplicate wells for 72hrs with or without 10ng/mL myristate acetate (PMA) + 2μM ionomycin.
Supernatants were analyzed by 22-plex Milliplex Map mouse cytokine/chemokine kit (Millipore, Mass, USA).
Data represent means ± SEM of triplicate wells in 3 experiments, n = 4–6 mice per experiment (TLI/ATS
group) and n = 5–7 mice per experiment (Untreated group). TLI/ATS: total lymphoid irradiation/anti-
thymocyte setum.
overall had early immune T-cell reconstitution. Follow-up of relapse rate in these patients is needed to
conﬁrm whether Treg infusion alters long-term GVT in the haplo-HSCT setting.
We are optimizing a protocol for iNKT expansion from different cellular therapy sources including
peripheral blood-derived mononuclear cells (Luszczek, Morales-Tirado, and Pillai, unpublished) using anti-
CD3. The goal of iNKT expansion is to apply them to suppress GVHD while simultaneously maintaining
GVT in HSCT, as well as to augment immunotherapy of tumors in the non-HSCT setting.
Suppression of immune responses by Treg makes them an attractive candidate for immunotherapy
[60]. However, the relative scarcity of this population the known expression of growth inhibitory
genes such as members at the SOCS family and PD-1 molecule, imposes limitations on their ex vivo
expansion. Breaking cell cycle arrest is critical to allow expansion; approaches including coculture with
immunomodulatory APCs have been examined to optimize Treg activation and expansion in vitro. To date,
these dominantly include TCR-triggering/costimulation (“Signals 1 and 2”), cytokine/cytokine receptor
modulation (“Signal 3”), and immunosuppressive and environmental compounds which achieve Signals
1–3. Signal 1 through the TCR and Signal 2 through costimulatory molecules (CD28) activate downstream
signaling pathways that ultimately lead to the activation of the transcription factors NFAT and NFκB,
breaking the constitutively nonproliferative state of resting Treg. Both in mice and humans, IL-2 and TGF-β
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FIGURE 4: Ex vivo expansion of CD3+CD4+CD25+CD127lo nTreg from adult peripheral blood (PB) and
umbilical cord blood (UCB)-derived mononuclear cells. (a) Total cell numbers of cultured nTreg. FACS-
sorted CD3+CD4+CD25+ T cells were cultured with Rapamycin and rhIL-2 for 21 days. (b) Fold expansion
(from baseline absolute number at start of expansion) of ex vivo expanded nTreg from PB and UCB.
are the two main cytokines used to augment Signal 3, prevent apoptosis, and possibly to sustain of FOXP3
expression. Rapamycin, a small molecule inhibitor of the mTOR-AKT pathway, promotes growth and
selective expansion of both human and murine CD3+CD4+CD25+FOXP3+Treg [61–63]. Environmental
compounds such as 1α, 25-dihydroxy vitamin D (vitamin D3) have been shown in murine studies to
augment expansion of antigen-speciﬁcT r e gin vivo and polyclonal Treg in vitro. A recent study of vitamin
D3 in humanTreg hasfurther demonstratedmodulation of FOXP3 andincrease in Treg suppressivefunction
[64].
Current expansion protocols use high doses of recombinant human IL-2 (≥100U/mL rhIL-2) that
may require continuous supply of the cytokine after infusion. We have found that, when coupled with
appropriate APC stimuli, low concentrations of rhIL-2 in combination with rapamycin can still achieve
signiﬁcantgrowthandexpansionofTregfromrelevanthumancellulartherapysources,asshowninFigure 4
(Morales-Tirado and Pillai, unpublished).
In addition to expansion of Treg, signiﬁcant efforts have been targeted to the induction of Treg (iTr)
from conventional (CD4+CD25negFoxp3neg) T cells. These populations differ from Treg in their modes
of induction, cytokine proﬁle, and mechanisms of suppressor activity. Reviews on these populations can
be found elsewhere [65–67]. Despite encouraging data with cellular expansions, there remains signiﬁcant
debate regarding stability of their suppressor phenotype (i.e., avoidance of reversion into an effector T-cell
population with proinﬂammatory rather than regulatory properties).
Although advances in chemotherapy and ancillary care have rendered pediatric leukemias largely
curable by chemotherapy alone, there remain many challenges in pediatric oncology which are amenable
to cellular immunotherapy. These include postchemotherapy consolidative immunotherapy for leukemias
and high-risk solid tumors such as advanced-stage or unfavorably located sarcomas, non-radio-responsive
central nervous system tumors, consolidative therapy after-transplant, and regulation of adverse immune
complications such as GVHD or delayed immune reconstitution after transplant.
Pretransplant conditioning regimens that enrich endogenously for regulatory cell populations hold
similar promise as methods of immunotherapy. Our group recently has performed a retrospective review in
a small cohort of pediatric patients treated for severe aplastic anemia (SAA) [68]. Although in few patients,
the data suggested comparable results between MSD and MUD HSCT using TLI/ATG in combination with
cyclophosphamide (CTX) conditioning. Future studies including a larger cohort of pediatric patients in
clinical trial to investigate TLI/ATG with CTX conditioning versus standard therapy are necessary to study
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mechanisms of induction tolerance. The outcomes of these studies will give us information applicable for
SAA and other diseases that are otherwise curable by application of HSCT.
Rapid and profound progress has been made in the past ﬁfty years in the clinical ﬁeld of
hematopoietic cell transplantation. However, ﬁne-tuning disease treatment, minimizing toxicity of the
therapy, GVHD prevention, stabilizing engraftment, and maintaining remission from malignant disease
by sustained GVT and tumor eradication remain the major challenges. Crosstalk and immunoregulation
by NKT and Treg, as discussed here, have clinical potential to separate GVHD and GVT after
allotransplantationanddeservefocusedtranslationalstudywithvariedconditioningregimensandinspeciﬁc
donor-recipient contexts.
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